Summit stock surges on $2 billion AstraZeneca investment

As reported by Markets-Economic Times

AstraZeneca is investing $2 billion in Summit Therapeutics, taking a potential 12% stake and partnering on cancer-drug development, including ivonescimab, while investors await upcoming FDA regulatory decisions.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Markets-Economic Times ↗

Market Samachar is a news aggregator. This article was originally published by Markets-Economic Times. Tap the button above to read the full story on their site.

COMPANIES Azad Engineering shares jump 10% as company expands GE Vernova's manufacturing footprint Stocks-Markets-Economic Times
INDIAN Anthropic’s Road to IPO: Funding, valuation, Claude growth and legal battles Markets-Economic Times
INDIAN Global Market: Japanese bond yields hover near multi-decade highs as inflation concerns persist Markets-Economic Times
INDIAN Adani Airport Holdings raises $120 million through local bond issue Markets-Economic Times
INDIAN Zydus hits 52-week high, can the optimism continue? mint - markets
INDIAN Crude oil shock and higher yields: Why Indian stock markets may remain volatile in near term - where should you invest? mint - markets
INDIAN Nifty Metal slips 5% in September post 29% 1 yr rally, October comeback ahead? Hindustan Zinc, NMDC, NALCO may shine mint - markets
INDIAN Tata Motors CV arm acquires 26% stake in Hyderabad-based e-mobility company, stock in red | Check details mint - markets

Summit stock surges on $2 billion AstraZeneca investment

More from Market Samachar